Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis

British Medical Journal

Volumn 316, Issue 7125, 1998, Pages 95-99

  Sarasin, François P ^a,c   Bounameaux, Henri ^b  

^a Department of Internal Medicine ^*

^b Div of Angiology and Haemostasis

^c University Canton   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5;

ARTICLE; BLEEDING; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; IATROGENIC DISEASE; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0032501685     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.316.7125.95     Document Type: Article

References (31)

1. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
2. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85:607-14.
3. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thromboembolism in apparently healthy men. N Engl J Med 1995;332:912-7.
4. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-6.
5. Koepke JA. Testing for hereditary hypercoagulability. Activated protein C resistance (editorial). Am J Clin Path 1996;106:161-2.
6. Vandenbroucke JP, Koster T, Briet T, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
7. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996;313:1127-30.
8. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpainter K, Hennenkens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2.
9. 506 → Gln mutation in the gene factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
10. Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczk C, Schneider B, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997;4:624-8.
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-8.
12. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873-6.
13. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lators G, Nicol P, et al. A comparison of six weeks with six months or oral anticoagulation after a first episode of venous thromboembolism: duration of anticoagulation trial study group. N Engl J Med 1995;332:1661-5.
14. Levine MN, Hirsh J, Gent M, Turpie AGG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.
15. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis. Acta Med Scand 1985;217:547-52.
16. Holmgren KAJ, Andersson G, Fagrell B, Johnsson H, Ljunberg B, Nilsson E, et al. One- month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985;218: 279-84.
17. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995;218:279-84.
18. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
19. Koopman MWM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
20. Monreal M, Ruiz J, Olazabal A, Arias A, Roca J. Deep venous thrombosis and the risk of pulmonary embolism: a systematic study. Chest 1992;102:677-81.
21. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1990;335:1816-28.
22. Carson JL, Kelley MA, Duff A, Palevitch M. The clinical course of pulmonary embolism. N Engl J Med 1992;326:1240-5.
23. Paraskos JA, Adelstein SJ, Smith RE, Rickman FD, Grossman W, Dexter L, et al. Late prognosis of acute pulmonary embolism. N Engl J Med 1973;289:55-8.
24. Claggett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism: Fourth American College of Chest Physicians consensus conference on antithrombotic therapy. Chest 1995;108(suppl):312-34S.
25. Levine M, Raskob GE, Landefeld CS, Hirsh J. Hemorrhagic complication of anticoagulant treatment: Fourth American College of Chest Physicians consensus conference on antithrombotic therapy. Chest 1995;108(suppl):276-90S.
26. Bounameaux H, de Moerloose P, Sarasin FP. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Blood Coagul Fibrinolysis 1996;7:507-14.
27. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:1710-1.
28. Desmarais S, De Moeloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996;347:1374-5.
29. Manten B, Rudi G, Westendorp J, Koster J, Reitsma PH, Rosendaal FR. Risk factors profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996;76:510-3.
30. 506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997;77:440-3.
31. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer NJ, Hennekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997;126:528-31.